The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Cycon, Kelly A ^a   Clements, James L ^a   Holtz, Renae ^a   Fuji, Hiroshi ^a   Murphy, Shawn P ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Antigen presentation; Costimulatory molecules; Lymphoma; MHC class II antigens; Tumour immunogenicity

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; IMMUNOGENICITY; LEUKEMIA L 1210; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE, TUMOR; CELLS, CULTURED; CLONE CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, INBRED DBA; T-LYMPHOCYTES;

EID: 68249147520     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03052.x     Document Type: Article

References (48)

1. Chambers C. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001 22 : 217 23.
2. Fujii S-I, Liu K, Smith C, Bonito A, Steinman R. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004 199 : 1607 18.
3. Foy T, Aruffo A, Bajorath J, Buhlmann J, Noelle R. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996 14 : 591 617. (Pubitemid 26130658)
4. Celia M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996 184 : 747 52.
5. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998 188 : 2357 68.
6. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990 144 : 4068 71.
7. James R, Edwards S, Hui K, Bassett P, Grosveld F. The effect of class II gene transfection on the tumorigenicity of the H-2K-negative mouse leukemia cell line K36.16. Immunology 1991 72 : 213 8.
8. Meazza R, Comes A, Orengo A, Ferrini S, Accolla R. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 2003 33 : 1183 92.
9. Mortara L, Castellani P, Meazza R et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 2006 12 : 3435 43.
10. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 1996 156 : 3821 7.
11. Thompson J, Dissanayake S, Ksander B, Knutson K, Disis M, Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 2006 66 : 1147 54.
12. Miller T, Lippman S, Spier C, Slymen D, Grogan T. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988 82 : 370 2.
13. Rimsza L, Roberts R, Miller T et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the leukemia and lymphoma molecular profiling project. Blood 2004 103 : 4251 8.
14. Roberts RA, Wright G, Rosenwald AR et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006 108 : 311 8.
15. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001 19 : 720 6.
16. Rimsza L, Farinha P, Fuchs D, Masoud H, Connors J, Gascoyne R. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007 48 : 542 6.
17. Amiot L, Onno M, Lamy T, Dauriac C, Le Prise P-Y, Fauchet R, Drenou B. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998 100 : 655 63.
18. Fuji H, Iribe H. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Cancer Res 1986 46 : 5541 7.
19. Murphy SP, Holtz R, Lewandowski N, Tomasi TB, Fuji H. DNA alkylating agents alleviate silencing of CIITA gene expression in L1210 lymphoma cells. J Immunol 2002 169 : 3085 93.
20. Murphy SP, Tomasi TB. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Mol Reprod Dev 1998 51 : 1 12.
21. Holtz R, Choi JC, Petroff MG, Piskurich JF, Murphy SP. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts. Biol Reprod 2003 69 : 915 24.
22. Chang C-H, Fontes J, Peterlin M, Flavell R. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility class II genes. J Exp Med 1994 180 : 1367 74.
23. Nikcevich K, Gordon K, Litjen Tan L, Hurst S, Kroepfl J, Gardinier M, Barrett T, Miller S. IFN-y-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol 1997 158 : 614 21.
24. Williamson C, Dutton E, Abbott C, Beechey C, Ball S, Peters J. Thirteen genes (Cebpb, E2f1, Tcf4, Cyp24, Pck1, Acra4, Edn3, Kcnb1, Mc3r, Ntsr, Cd40, Plcg1 and Rcad) that probably lie in the distal imprinting region of mouse chromosome 2 are not monoallelically expressed. Genet Res 1995 65 : 83 93.
25. Zhang P, Sun D, Ke Y, Kaplan H, Shao H. The net effect of costimulatory blockers is dependent on the subset and activation status of the autoreactive T cells. J Immunol 2007 178 : 474 9.
26. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom K. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994 179 : 523 32.
27. Ranheim E, Kipps T. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993 177 : 925 35.
28. Chaperot L, Plumas J, Jacob M-C, Bost F, Molens J-P, Sotto J-J, Bensa J-C. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999 27 : 479 88.
29. Buhlmann J, Fey T, Aruff A et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995 2 : 645 53.
30. Shinde S, Wu Y, Guo Y, Niu Q, Xu J, Grewal I, Flavell R, Liu Y. CD40L is important for induction of, but not response to, costimulatory activity; ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J Immunol 1996 157 : 2764 8.
31. Lala P, Johnson G, Battye F, Nossal G. Maturation of B lymphocytes: concurrent appearance of increasing Ig, Ia, and mitogen responsiveness. J Immunol 1979 122 : 334 41.
32. Tarlinton D. Direct demonstration of MHC class II surface expression on murine pre-B cells. Int Immunol 1994 5 : 1629 35.
33. Miki N, Hatano M, Wakita K, Imoto S, Nishikawa S, Nishikawa S-I, Tokuhisa T. Role of I-A molecules in early stages of B cell maturation. J Immunol 1992 149 : 801 7.
34. Borrello M, Phipps R. The B/Macrophage cell: an elusive link between CD5+ B cells and macrophages. Immunol Today 1996 17 : 471 5.
35. Bjorck P, Kincade P. Cutting edge: CD19+ pro-B cells can give rise to dendritic cells in vitro. J Immunol 1998 161 : 5795 9.
36. Montecino-Rodrigueza E, Dorshkind K. New perspectives in B-1 B cell development and function. Trends Immunol 2006 27 : 428 33.
37. Berland R, Wortis H. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002 20 : 253 300.
38. Mongini C, Sanchez Lockhart M, Waldner C, Alvarez E, Gravisaco M, Roig M, Hajos S. Enhancement of anti-tumor immunity in syngeneic mice after MHC class II gene transfection. Br J Cancer 1996 74 : 258 63.
39. Armstrong T, Clements V, Martin B, Ting J-Y, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997 94 : 6886 91.
40. Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ lymphocytes. J Immunol 1998 160 : 661 6.
41. Dissanayake S, Thompson J, Bosch J, Clements V, Chen P, Ksander B, Ostrand-Rosenberg S. Activation of tumor-specific CD4+ T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004 64 : 1867 74.
42. Altomonte M, Fonsatti E, Visintin A, Maio M. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 2003 22 : 6564 9.
43. Seliger B, Maeurerb M, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000 21 : 455 64.
44. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H, Frutiger Y, Grogan TM. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000 6 : 3904 9.
45. Lippman SM, Spier CM, Miller TP, Slymen DJ, Rybski JA, Grogan TM. Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 1990 3 : 361 7.
46. List A, Spier C, Miller T, Grogan T. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 1993 3 : 398 403.
47. Medeiros L, Picker L, Gelb A, Strickler J, Brain S, Weiss L, Horning S, Warnke R. Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphoma. J Clin Oncol 1989 7 : 1009 17.
48. Linderoth J, Ehinger M, Jerkeman M et al. CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leuk Lymphoma 2007 48 : 1774 9.